Article info
Epidemiology
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
- Correspondence to Dr Pedro M Machado, Centre for Rheumatology, University College London, London, UK; p.machado{at}ucl.ac.uk
Citation
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
Publication history
- Received September 10, 2021
- Accepted December 8, 2021
- First published December 31, 2021.
Online issue publication
October 18, 2023
Article Versions
- Previous version (15 November 2022).
- Previous version (15 November 2022).
- You are viewing the most recent version of this article.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage